Trial Profile
A Phase 1b Multi-Center, Randomized, Double-Blind, Multi−Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD−1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Izencitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Theravance Biopharma
- 20 Apr 2020 Results published in the Theravance Biopharma Media Release.
- 20 Apr 2020 According to an Theravance Biopharma media release, data from this study were published in the Journal of Crohn's and Colitis.
- 21 May 2019 According to a Theravance Biopharma media release, data from this study were presented at the Digestive Disease Week (DDW) 2019.